Adjunct Intraarterial or Intravenous Tirofiban Versus No Tirofiban After Successful Recanalization of Basilar Artery Occlusion Stroke: The BASILAR Registry.
Huagang LiDongsheng JuZhaojun TaoJiayin WangThanh N NguyenJeffrey L SaverRaul Gomes NogueiraChang LiuQing-Wu YangZhong Ming QiuCongguo YinDong SunShudong LiuPublished in: Journal of the American Heart Association (2024)
Intraarterial+intravenous rather than intravenous tirofiban improved clinical outcomes without increasing the frequency of symptomatic ICH among patients with basilar artery occlusion after successful endovascular treatment. Further studies are needed to delineate the roles of intraarterial+intravenous tirofiban in patients with basilar artery occlusion receiving endovascular treatment.